Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study.

Publication Year: 2024

DOI:
10.1186/s12877-024-04719-6

PMCID:
PMC10826072

PMID:
38287253

Journal Information

Full Title: BMC Geriatr

Abbreviation: BMC Geriatr

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Geriatrics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. It was approved by a national independent Ethics Committee (“Comité de Protection des Personnes Ile de France III”) and written informed consent was obtained from all subjects participating in the trial. Consent for publicationNot applicable. Competing interestsB. Fougère: consultancies, honoraria, advisory board, speakers: AstraZeneca, Bayer, Biogen, Biophitys, BMS, Boehringer-Ingelheim, CSL Vifor, GSK, MSD, Nestlé, Novartis, Pfizer.F. Puisieux: consultancies, honoraria, advisory board, speakers’ fees: Bayer, BMS, Boehringer-Ingelheim, CSL Vifor, GSK, MSD, Sanofi, Novartis, Pfizer.P. Chevalet: speaker’s fees for Vifor.C. Annweiler: no conflict of interest.E. Michel: no conflict of interest.L. Joly: no conflict of interest.F. Blanc: no conflict of interest.A. El Azouzi: no conflict of interest.V. Desré-Follet: employee of CSL Vifor, France.P. Cacoub: consultancies, honoraria, advisory board, speakers’ fees: Alnylam, Innotech, Mylan, Pfizer, Servier, and Vifor. Competing interests B. Fougère: consultancies, honoraria, advisory board, speakers: AstraZeneca, Bayer, Biogen, Biophitys, BMS, Boehringer-Ingelheim, CSL Vifor, GSK, MSD, Nestlé, Novartis, Pfizer. F. Puisieux: consultancies, honoraria, advisory board, speakers’ fees: Bayer, BMS, Boehringer-Ingelheim, CSL Vifor, GSK, MSD, Sanofi, Novartis, Pfizer. P. Chevalet: speaker’s fees for Vifor. C. Annweiler: no conflict of interest. E. Michel: no conflict of interest. L. Joly: no conflict of interest. F. Blanc: no conflict of interest. A. El Azouzi: no conflict of interest. V. Desré-Follet: employee of CSL Vifor, France. P. Cacoub: consultancies, honoraria, advisory board, speakers’ fees: Alnylam, Innotech, Mylan, Pfizer, Servier, and Vifor."

Evidence found in paper:

"Funding The CARENFER PA study was funded by CSL VIFOR."

Evidence found in paper:

"Trial registration NCT05514951."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025